drugset / Trial / NCT04189276

Safety and Efficacy of Therapeutic Hepatitis B Adenovirus Injection (T101) Combined With Nucleoside (Acid) Analogues in Chronic Hepatitis B Patients

NCT04189276

Phase 2 Unknown 100 enrolled Tasly Tianjin Biopharmaceutical Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

A multi-center, randomized, open-label, group controlled study to evaluate the safety and efficacy of T101 combined with nucleoside (acid) analogues in chronic hepatitis B patients.

Timeline

Start
2019-12-10
Primary completion
2021-06-30
Completion
2021-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Entecavir Small molecule
Comparator Peginterferon alfa-2b Protein / enzyme biologic
Comparator TELIMOMAB ARITOX Vaccine Other
Comparator Tenofovir Small molecule